Editas Medicine Inc (NASDAQ:EDIT) has a beta value of 2.09 and has seen 1.65 million shares traded in the last trading session. The company, currently valued at $152.36M, closed the last trade at $1.82 per share which meant it gained $0.05 on the day or 2.82% during that session. The EDIT stock price is -241.76% off its 52-week high price of $6.22 and 50.0% above the 52-week low of $0.91.
The consensus among analysts is that Editas Medicine Inc (EDIT) is Buy stock at the moment, with a recommendation rating of 2.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 9 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.37.
Editas Medicine Inc (NASDAQ:EDIT) trade information
Sporting 2.82% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the EDIT stock price touched $1.82 or saw a rise of 6.67%. Year-to-date, Editas Medicine Inc shares have moved 43.31%, while the 5-day performance has seen it change 10.30%. Over the past 30 days, the shares of Editas Medicine Inc (NASDAQ:EDIT) have changed 10.98%.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 84.83% from current levels. The projected low price target is $5.0 while the price target rests at a high of $35.0. In that case, then, we find that the current price level is -1823.08% off the targeted high while a plunge would see the stock gain -174.73% from current levels.
Editas Medicine Inc (EDIT) estimates and forecasts
The company’s shares have lost -17.27% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -59.74%.
12 analysts offering their estimates for the company have set an average revenue estimate of 1.8M for the current quarter. 12 have an estimated revenue figure of 1.85M for the next ending quarter. Year-ago sales stood 513k and 61k respectively for this quarter and the next, and analysts expect sales will grow by 251.82% for the current quarter and -59.74% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.48% over the past 5 years. Earnings growth for 2025 is a modest 36.08% while over the next 5 years, the company’s earnings are expected to increase by 26.11%.
EDIT Dividends
Editas Medicine Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Editas Medicine Inc (NASDAQ:EDIT)’s Major holders
The top two institutional holders are VANGUARD GROUP INC with over 8.03 million shares worth more than $37.51 million. As of 2024-06-30, VANGUARD GROUP INC held 9.7589% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 7.78 million shares as of 2024-06-30. The firm’s total holdings are worth over $36.34 million and represent 9.4551% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 3.10% shares in the company for having 2.59 shares of worth $4.72 million while later fund manager owns 2.21 shares of worth $4.03 million as of Mar 31, 2025 , which makes it owner of about 2.64% of company’s outstanding stock.
